CY1108742T1 - Κρυσταλλικη μορφη της μηλεϊνικης ασεναπινης - Google Patents

Κρυσταλλικη μορφη της μηλεϊνικης ασεναπινης

Info

Publication number
CY1108742T1
CY1108742T1 CY20091100111T CY091100111T CY1108742T1 CY 1108742 T1 CY1108742 T1 CY 1108742T1 CY 20091100111 T CY20091100111 T CY 20091100111T CY 091100111 T CY091100111 T CY 091100111T CY 1108742 T1 CY1108742 T1 CY 1108742T1
Authority
CY
Cyprus
Prior art keywords
asenapin
malenic
crystal form
crystalline form
orthorhombic
Prior art date
Application number
CY20091100111T
Other languages
English (en)
Inventor
Gerhardus Johannes Heeres
Original Assignee
N.V. Organon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36617328&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1108742(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by N.V. Organon filed Critical N.V. Organon
Publication of CY1108742T1 publication Critical patent/CY1108742T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

Η εφεύρεση αφορά σε μια ορθορομβική κρυσταλλική μορφή της ένωσης trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz [2,3:6,7] oxepino [4,5-c] pyrrole (Z)-2-butenedioate, σε μεθόδους παρασκευής αυτής της κρυσταλλικής μορφής και σε φαρμακευτικές συνθέσεις που περιέχουν μια ορθορομβική κρυσταλλική μορφή.
CY20091100111T 2005-04-07 2009-01-30 Κρυσταλλικη μορφη της μηλεϊνικης ασεναπινης CY1108742T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05102742 2005-04-07
EP05102969 2005-04-14
EP06725622A EP1917267B1 (en) 2005-04-07 2006-04-06 Crystal form of asenapine maleate

Publications (1)

Publication Number Publication Date
CY1108742T1 true CY1108742T1 (el) 2014-04-09

Family

ID=36617328

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20071101258T CY1106902T1 (el) 2005-04-07 2007-10-02 Κρυσταλλικη μορφη μηλεϊνικης ασεναπινης
CY20091100111T CY1108742T1 (el) 2005-04-07 2009-01-30 Κρυσταλλικη μορφη της μηλεϊνικης ασεναπινης

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20071101258T CY1106902T1 (el) 2005-04-07 2007-10-02 Κρυσταλλικη μορφη μηλεϊνικης ασεναπινης

Country Status (31)

Country Link
EP (2) EP1710245B1 (el)
JP (1) JP5058151B2 (el)
KR (1) KR101422843B1 (el)
AR (1) AR056306A1 (el)
AT (2) ATE370954T1 (el)
AU (1) AU2006231617B2 (el)
BR (1) BRPI0609741A8 (el)
CA (1) CA2603509C (el)
CY (2) CY1106902T1 (el)
DE (2) DE602006000080T2 (el)
DK (2) DK1710245T3 (el)
DO (1) DOP2006000082A (el)
ES (2) ES2318742T3 (el)
GT (1) GT200600135A (el)
HN (1) HN2006014095A (el)
HR (1) HRP20070429T3 (el)
IL (1) IL186355A (el)
MX (1) MX2007012445A (el)
MY (1) MY137969A (el)
NO (1) NO340520B1 (el)
NZ (1) NZ562124A (el)
PE (1) PE20061311A1 (el)
PL (2) PL1710245T3 (el)
PT (2) PT1710245E (el)
RS (1) RS50532B (el)
RU (1) RU2405786C2 (el)
SI (2) SI1710245T1 (el)
SV (1) SV2006002473A (el)
TW (1) TWI364423B (el)
UY (1) UY29459A1 (el)
WO (1) WO2006106135A1 (el)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2078024A1 (en) * 2006-10-06 2009-07-15 N.V. Organon Amorphous asenapine and processes for preparing same
JP5801295B2 (ja) * 2009-06-24 2015-10-28 メルク・シャープ・エンド・ドーム・ベー・フェー アセナピンを含有する注射可能な配合物およびそれを用いた処置方法
WO2011159903A2 (en) * 2010-06-18 2011-12-22 Dr. Reddy's Laboratories Ltd. Asenapine maleate
WO2012066565A2 (en) * 2010-11-16 2012-05-24 Cadila Healthcare Limited Asenapine maleate amorphous and crystalline form and process for preparation thereof
EP2468750A1 (en) 2010-12-13 2012-06-27 Chemo Ibérica, S.A. Polymorphic forms of asenapine maleate and processes for their preparation
WO2012123325A1 (en) 2011-03-11 2012-09-20 Medichem S.A. NEW CRYSTAL FORMS OF THE SALT OF TRANS-5-CHLORO-2-METHYL-2,3,3A,12b-TETRAHYDRO-1H-DIBENZO[2,3:6,7]OXEPINO[4,5-c]PYRROLE WITH MALEIC ACID
ITMI20110734A1 (it) * 2011-05-02 2012-11-03 Olon Spa Sali cristallini di asenapina
EP2524920A1 (en) 2011-05-17 2012-11-21 Sandoz AG Novel Crystalline Asenapine Hydrochloride Salt Forms
EP2524919A1 (en) 2011-05-17 2012-11-21 Sandoz AG Novel crystalline salts of Asenapine with organic Di-acids and Tri-acids
EP2524921A1 (en) 2011-05-17 2012-11-21 Sandoz AG Novel Crystalline Salts of Asenapine
JP6014656B2 (ja) * 2011-05-18 2016-10-25 ラビラトリオス レスビ エス エレ 化合物の多形体
US9533994B2 (en) 2011-05-18 2017-01-03 Laboratorios Lesvi S.L. Monoclinic crystalline form of asenapine maleate with a specific particle size distribution
EP2572703A1 (en) 2011-09-21 2013-03-27 Hexal AG Compressed oral dosage form for asenapine maleate
WO2013041604A1 (en) 2011-09-21 2013-03-28 Sandoz Ag Crystal form of asenapine maleate
JP6005741B2 (ja) * 2012-07-26 2016-10-12 久光製薬株式会社 貼付剤及びその製造方法
ITMI20121810A1 (it) 2012-10-24 2014-04-25 Chemo Iberica Sa Poliformi di maleato di asenapina e processo per la loro preparazione
WO2014090386A1 (en) 2012-12-11 2014-06-19 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Orally disintegrating tablet containing asenapine
WO2014127786A1 (en) 2013-02-22 2014-08-28 Zentiva, K.S. Orally disintegrating pharmaceutical composition comprising asenapine
US10786520B2 (en) 2015-09-02 2020-09-29 Eloxx Pharmaceuticals Ltd. Aminoglycoside derivatives and uses thereof in treating genetic disorders
EP3558276A1 (en) 2016-12-20 2019-10-30 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
MX2019007391A (es) 2016-12-20 2019-08-16 Lts Lohmann Therapie Systeme Ag Sistema terapeutico transdermico que contiene asenapina.
JP2020525545A (ja) 2017-06-26 2020-08-27 エルテーエス ローマン テラピー−ジステーメ アーゲー アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム
AU2019291060B2 (en) 2018-06-20 2024-09-05 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7605526A (nl) * 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
ATE167057T1 (de) * 1994-03-02 1998-06-15 Akzo Nobel Nv Sublinguales oder bukkales arzneimittel
WO1999032108A1 (en) * 1997-12-19 1999-07-01 Akzo Nobel N.V. Org-5222 in the treatment of depression
TWI327915B (en) * 2003-06-12 2010-08-01 Organon Nv Pharmaceutical composition comprising antipsychotic agent and use of the antipsychotic agent for treating patients with overweight

Also Published As

Publication number Publication date
PL1917267T3 (pl) 2009-06-30
ES2318742T3 (es) 2009-05-01
KR101422843B1 (ko) 2014-07-24
SI1917267T1 (sl) 2009-04-30
DE602006004463D1 (de) 2009-02-05
KR20080005253A (ko) 2008-01-10
MX2007012445A (es) 2007-11-07
HN2006014095A (es) 2010-08-19
DE602006000080T2 (de) 2008-05-15
EP1710245A1 (en) 2006-10-11
AR056306A1 (es) 2007-10-03
GT200600135A (es) 2006-11-07
JP5058151B2 (ja) 2012-10-24
EP1917267B1 (en) 2008-12-24
IL186355A (en) 2016-05-31
PE20061311A1 (es) 2007-02-09
WO2006106135A1 (en) 2006-10-12
EP1710245B1 (en) 2007-08-22
ATE418556T1 (de) 2009-01-15
ATE370954T1 (de) 2007-09-15
CY1106902T1 (el) 2012-09-26
ES2293626T3 (es) 2008-03-16
BRPI0609741A8 (pt) 2018-03-13
PT1710245E (pt) 2007-10-03
DK1710245T3 (da) 2007-12-03
DOP2006000082A (es) 2006-11-30
BRPI0609741A2 (pt) 2010-04-27
NO340520B1 (no) 2017-05-02
PT1917267E (pt) 2009-02-04
NZ562124A (en) 2010-07-30
SV2006002473A (es) 2009-11-24
CA2603509A1 (en) 2006-10-12
RU2007141198A (ru) 2009-05-20
TWI364423B (en) 2012-05-21
IL186355A0 (en) 2008-01-20
EP1917267A1 (en) 2008-05-07
DK1917267T3 (da) 2009-04-14
AU2006231617B2 (en) 2010-06-03
HRP20070429T3 (en) 2007-11-30
RU2405786C2 (ru) 2010-12-10
AU2006231617A1 (en) 2006-10-12
CA2603509C (en) 2013-12-03
NO20075142L (no) 2007-11-05
JP2008534656A (ja) 2008-08-28
MY137969A (en) 2009-04-30
PL1710245T3 (pl) 2008-01-31
TW200722428A (en) 2007-06-16
UY29459A1 (es) 2006-11-30
RS50532B (sr) 2010-05-07
DE602006000080D1 (de) 2007-10-04
SI1710245T1 (sl) 2007-12-31

Similar Documents

Publication Publication Date Title
CY1108742T1 (el) Κρυσταλλικη μορφη της μηλεϊνικης ασεναπινης
UA93044C2 (en) urn:schemas-microsoft-com:office:smarttagsCRYSTALFORM OF ASENAPINE MALEATE
BRPI0605921B8 (pt) compostos orgânicos, seus métodos de preparo e uso, bem como composições farmacêuticas
NO20080129L (no) Fremgangsmate for fremstilling av dihydrokinazoliner
MX2007005221A (es) Formas cristalinas de ascomicina y preparacion de ellas.
CY1114793T1 (el) Παραγωγα αμινοπυραζολιου
CY1112653T1 (el) Κρυσταλλικες τροποποιησεις της πυρακλοστροβινης
CY1110209T1 (el) Υποκατεστημενες ενωσεις βενζο(d)ισοξαζολ-3-υλ-αμινης σαν αναλγητικα
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
TW200624588A (en) Organometallic compounds
ES2368594T3 (es) Derivados sustituidos de ciclohexilmetilo.
CY1114303T1 (el) Νεο οξινο θειικο αλας
EA201000642A1 (ru) 2'-фтор-2'-дезокситетрагидроуридины в качестве ингибиторов цитидиндеаминазы
CY1109369T1 (el) Υποκατεστημενες πυρρολοπυριδινες, οι ενωσεις που τις περιεχουν, η διαδικασια παρασκευης τους και η χρηση τους
WO2005070884A3 (en) Heterocyclic compounds useful as growth hormone secretagogues
MX2009007436A (es) Derivados espirociclicos de acido tetronico.
CY1110034T1 (el) Παραγωγα 1,2,4,5-τετραϋδρο-3h-βενζαζεπινων, μεθοδος παρασκευης αυτων και οι φαρμακευτικες συνθεσεις που τα περιεχουν
ATE393764T1 (de) Polymorphe formen von valsartan
EA201070804A1 (ru) (аза)индольное производное, замещенное по положению 5, содержащая его фармацевтическая композиция, промежуточные соединения и способ их получения
EA200800393A1 (ru) Новые соединения-аналоги камптотецина, способ их получения и фармацевтические композиции, которые их содержат
DK1869038T3 (da) Substituerede 5,6,7,8-tetrahydro-imidazol[1,2-a]pyridin-2-ylamin-forbindelser og deres anvendelse til fremstilling af lægemidler
CY1107028T1 (el) Παραγωγα ινδανυλ-πιπεραζινων μεθοδος παρασκευης αυτων και οι φαρμακευτικες συνθεσεις που τα περιεχουν
MX2007002833A (es) Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorios.
DE602005016282D1 (de) Verfahren zur herstellung von camptothecin-derivaten
TW200613308A (en) Cyclobutanetetracarboxylate compound and preparation method thereof